Important factors affecting GLP-1 market demand and take-up include: The need for better long-term data on the safety and efficacy of use for the designated indications The rapidly expanding list of potential new indications for the drugs, including chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease, and Alzheimer's disease The number of similar drugs in the development pipeline Price point versus competition, which affects affordability and insurance coverage Marketing efforts of the manufacturers, supply and distribution constraints
, ,
declares having received consulting honoraria from ANI Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and Oramed, and stock options from AltPep
We explore how close researchers may be to a cure, including promising gene therapy clinical trials, and what experts say still needs long-term study
Tapering Off GLP-1 Medications Pinto says people taking a GLP-1 who want to adjust their dosing for whatever reason finances, changes in insurance coverage, or they no longer want to be on the medication should talk with their doctor about the best path forward
